» Articles » PMID: 19822218

Pulmonary, Gonadal, and Central Nervous System Status After Bone Marrow Transplantation for Sickle Cell Disease

Abstract

We conducted a prospective, multicenter investigation of human-leukocyte antigen (HLA) identical sibling bone marrow transplantation (BMT) in children with severe sickle cell disease (SCD) between 1991 and 2000. To determine if children were protected from complications of SCD after successful BMT, we extended our initial study of BMT for SCD to conduct assessments of the central nervous system (CNS) and of pulmonary function 2 or more years after transplantation. In addition, the impact on gonadal function was studied. After BMT, patients with stroke who had stable engraftment of donor cells experienced no subsequent stroke events after BMT, and brain magnetic resonance imaging (MRI) exams demonstrated stable or improved appearance. However, 2 patients with graft rejection had a second stroke after BMT. After transplantation, most patients also had unchanged or improved pulmonary function. Among the 11 patients who had restrictive lung changes at baseline, 5 were improved and 6 had persistent restrictive disease after BMT. Of the 2 patients who had obstructive changes at baseline, 1 improved and 1 had worsened obstructive disease after BMT. There was, however, significant gonadal toxicity after BMT, particularly among female recipients. In summary, individuals who had stable donor engraftment did not experience sickle-related complications after BMT, and were protected from progressive CNS and pulmonary disease.

Citing Articles

Late effects of hemopoietic stem cell transplant for sickle cell disease: monitoring and management.

Goldenberg M, Lanzkron S, Pecker L Expert Rev Hematol. 2024; 17(12):891-905.

PMID: 39499235 PMC: 11669372. DOI: 10.1080/17474086.2024.2423368.


Reproductive Health Assessment and Reports of Fertility Counseling in Pediatric and Adolescent Patients with Sickle Cell Disease After Hematopoietic Cell Transplantation.

George S, Veludhandi A, Xiang Y, Liu K, Stenger E, Arnold S Transplant Cell Ther. 2024; 30(9):912.e1-912.e13.

PMID: 38972510 PMC: 11344653. DOI: 10.1016/j.jtct.2024.06.029.


Long-Term Ovarian Function Assessment After Haematopoietic Stem Cell Transplantation in Female Sickle Cell Anaemia Survivors.

Olowoselu O, Okunade K, Oyedeji O, Davies N, Ajie O, Adewoyin A Cureus. 2024; 16(4):e58195.

PMID: 38741860 PMC: 11090072. DOI: 10.7759/cureus.58195.


Hematopoietic Stem Cell Transplantation in Sickle Cell Disease: A Multidimentional Review.

Rostami T, Rad S, Rostami M, Mirhosseini S, Alemi H, Khavandgar N Cell Transplant. 2024; 33:9636897241246351.

PMID: 38680015 PMC: 11057353. DOI: 10.1177/09636897241246351.


Effect of allogeneic hematopoietic stem cell transplantation on sickle cell disease-related organ complications: A systematic review and meta-analysis.

Dovern E, Aydin M, DeBaun M, Alizade K, Biemond B, Nur E Am J Hematol. 2024; 99(6):1129-1141.

PMID: 38517255 PMC: 11730142. DOI: 10.1002/ajh.27297.


References
1.
Gladwin M, Sachdev V, Jison M, Shizukuda Y, Plehn J, Minter K . Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004; 350(9):886-95. DOI: 10.1056/NEJMoa035477. View

2.
POWARS D, Adams R, Nichols F, Milner P, CHARACHE S, Sarnaik S . Delayed intracranial hemorrhage following cerebral infarction in sickle cell anemia. J Assoc Acad Minor Phys. 1990; 1(3):79-82. View

3.
Platt O, Rosenstock W, Espeland M . Influence of sickle hemoglobinopathies on growth and development. N Engl J Med. 1984; 311(1):7-12. DOI: 10.1056/NEJM198407053110102. View

4.
Adams R, McKie V, Nichols F, Carl E, Zhang D, McKie K . The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med. 1992; 326(9):605-10. DOI: 10.1056/NEJM199202273260905. View

5.
Walters M, Sullivan K, Bernaudin F, Souillet G, Vannier J, Johnson F . Neurologic complications after allogeneic marrow transplantation for sickle cell anemia. Blood. 1995; 85(4):879-84. View